drugset / Trial / NCT01714466

Pharmacodynamic and Clinical Evaluation of Dose and Taste-optimised Low Volume PEG-based Bowel Cleansing Solutions Using the Split-dosing Intake Regimen in Healthy Subjects and in Subjects Undergoing Screening Colonoscopy

NCT01714466

Phase 2 Completed 240 enrolled Norgine
RandomizedParallel-groupOpen-labelTreatment

Summary

A study to assess the pharmacodynamics, safety and tolerability of a PEG-based bowel cleansing solution (MOVIPREP®)

Timeline

Start
2012-10
Primary completion
2013-07
Completion
2014-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Moviprep Other / unclassified 2000 ml
Subject polyethylene glycol Other / unclassified 1000 ml
Subject polyethylene glycol Other / unclassified 1250 ml

Indications